RSV-related hospital admissions in a subset of hospitals in England and Scotland: A real-world study (2018–2023)

Le résumé fourni par la source

Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI), though its healthcare burden and costs are insufficiently described among adults in the United Kingdom. With the recent availability of vaccines, understanding RSV-related secondary care burden is essential. Routinely collected adult ARI hospitalization data between 2018 and 2023 from four English National Health Service (NHS) trusts and a Scottish Health Board were linked to RSV, influenza, and coronavirus disease 2019 (COVID-19) microbiology tests and results. ARI incidence risk and ARI-related hospitalizations overall and per pathogen were described (including mortality, hospitalization length of stay [LoS], intensive care unit [ICU] admissions/LoS, and costs). RSV-positive microbiology tests and International Classification of Diseases (ICD)-10 RSV diagnoses were compared. In both settings, incidence risk of first ARI hospitalizations increased from 2018/19 to 2022/23. Of RSV-tested hospitalizations, 7.0% (England) and 4.1% (Scotland) had an RSV-positive test. Of these, 7.4% and 8.0% died in hospital, respectively; similar proportions were observed for influenza (5.5% and 5.0%). In England and Scotland, RSV-positive hospitalization LoS was 5 and 6 d, comparable to COVID-19 (8 and 10) and influenza (4 and 3). ICU admittance and direct costs per hospitalization were generally comparable across pathogens. In England and Scotland, 63.5% and 33.7% of RSV-positive hospitalizations had an RSV ICD-10 code, respectively. Among English and Scottish adults, RSV-positive hospitalizations had substantial healthcare resource utilization, comparable to COVID-19- and influenza-positive hospitalizations. ICD-10 codes are limited proxies for identifying RSV hospitalizations. Broadening RSV adult vaccination recommendations may reduce the RSV secondary care burden.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.